. . . . . . . "[Taken together our data identify Tempol as an agent with potential therapeutic activity targeting expression of HIF2? in VHL-deficient clear cell kidney cancer and illustrate the importance of studying biochemical processes at relevant physiological O2 levels.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:12:18+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .